The purpose of the study is to analyze the changes in the ambulatory
pharmacotherapy cost of kidney transplant patients in Bulgaria during the years
2006-2011 and the factors influencing it. It is a prospective cost study
of changes in ambulatory pharmacotherapy cost. The cost of pharmacotherapy was calculated per patient per year and per
month on average. In total, 21 therapeutic
schemes were prescribed for 589 individuals per year on average. Most often,
the prescribed therapeutic scheme was ciclosporin + mycophenolate, 38% to
39% of all cases during 2006 and 2011 respectively. Average cost of therapy
differs in great interval and depends on age of the patients, place of
transplantation, life with the graft, development of the citomegalovirus
infection etc. Our study shows that the average monthly cost of pharmacotherapy
decreases during 2006-2011, as a result of introduction of generic immune
suppressors. All evaluated factors influence the statistically significant cost
of pharmacotherapy.
References
[1]
E. Naumova, P. Panchev, P. J. Simeonov, et al., “Organ Transplantation in Bulgaria,” Cell Tissue Bank, Vol. 9, No. 4, 2008, pp. 337-342. http://dx.doi.org/10.1007/s10561-007-9035-2
[2]
M. First, “Immunosupressive Agents and Their Actions,” Transplantation Proceedings, Vol. 34, No. 5, 2002, pp. 1369-1371. http://dx.doi.org/10.1016/S0041-1345(02)02893-2
[3]
A. H. Miners, G. Yao, J. Raftery and R. S. Taylor, “Economic Evaluations of Calcineurin Inhibitors in Renal Transplantation: A Literature Review,” Pharmacoeconomics, Vol. 25, No. 11, 2007, pp. 935-947. http://dx.doi.org/10.2165/00019053-200725110-00004
[4]
R. L. Morton, K. Howard, A. C. Webster, G. Wong and J. C. Craig, “The Cost-Effectiveness of Induction Immunosuppression in Kidney Transplantation,” Nephrology Dialysis Transplantation, Vol. 24, No. 7, 2009, pp. 2258-2269. http://dx.doi.org/10.1093/ndt/gfp174
[5]
S. D. Sullivan, L. P. Garrison Jr. and J. H. Best, “The Cost Effectiveness of Mycophenolate Mofetil in the First Year after Primary Cadaveric Transplant. U.S. Renal Transplant Mycophenolate Mofetil Study Group,” Journal of the American Society of Nephrology, Vol. 8, No. 10, 1997, pp. 1592-1598.
[6]
D. Chaib-Eddour, H. Chaib-Eddour, J. Malaise, et al., “Cost of Renal Transplant in Belgium,” Transplantation Proceedings, Vol. 37, No. 6, 2005, pp. 2819-2820. http://dx.doi.org/10.1016/j.transproceed.2005.05.035
[7]
J. Chetwynd and C. Swainson, “The Cost of Renal Transplants,” The New Zealand Medical Journal, Vol. 100, No. 822, 1987, p. 247.
[8]
A. G. Diethelm, J. A. Lee, S. L. O’Brien, et al., “Cost Analysis of Renal Transplantation in a Veterans Administration Hospital,” Military Medicine, Vol. 142, 1977, p. 286.
[9]
M. A. Gentil, F. González-Roncero, C. Cantarell, et al., “Effect of New Immunosuppressive Regimens on Cost of Renal Transplant Maintenance Immunosuppression,” Transplantation Proceedings, Vol. 37, No. 3, 2005, pp. 1441-1442. http://dx.doi.org/10.1016/j.transproceed.2005.02.012
[10]
E. K. L. Lee and P. L. Tseng, “Retrospective Study on the Utilization and Cost of Immunosuppressive Agents among Kidney Transplant Recipients in Taiwan: A 5-Year Review,” Transplantation Proceedings, Vol. 40, No. 7, 2008, pp. 2214-2271. http://dx.doi.org/10.1016/j.transproceed.2008.07.003
[11]
E. K. L. Lee, T. M. Cham and P. L. Tseng, “A Retrospective Study on the Utilization of and Expenditure for Immunosuppressants for Organ Transplant Recipients in Taiwan—Updated to 2006,” Transplantation Proceedings, Vol. 42, No. 3, 2010, pp. 961-965. http://dx.doi.org/10.1016/j.transproceed.2010.03.013
[12]
E. F. Yena, K. Hardinger, D. C. Brennan, et al., “CostEffectiveness of Extending Medicare Coverage of Immunosuppressive Medications to the Life of a Kidney Transplant,” American Journal of Transplantation, Vol. 4, No. 10, 2004, pp. 1703-1708. http://dx.doi.org/10.1111/j.1600-6143.2004.00565.x
[13]
National Peoples Assembly, “Law for Organ, Tissues and Cells Transplantation,” Governmental Newspaper, Vol. 83, 2003.
[14]
Ministry of Health, “Regulation 34 for the Order of Payment from the Governmental Budget the Therapy of the Bulgarian Citizens That Is Not Covered by the Obligatory Health Insurance,” Governmental Newspaper, Vol. 95, 2005.
[15]
S. K. Takemoto, B. W. Pinsky, M. A. Schnitzler, et al., “A Retrospective Analysis of Immunosupression Compliance, Dose Reduction and discontinuation in Kidney Transplant Patient,” American Journal of Transplantation, Vol. 7, No. 12, 2007, pp. 2704-2711. http://dx.doi.org/10.1111/j.1600-6143.2007.01966.x
[16]
E. Nemati, A. R. Saadat, M. Hashemi, et al., “Causes of Rehospitalization after Renal Transplantation; Does Age of Recipient Matter?” Transplantation Proceedings, Vol. 39, No. 4, 2007, pp. 970-973. http://dx.doi.org/10.1016/j.transproceed.2007.03.078
[17]
T. F. Page and R. S. Woodward, “Cost of Lifetime Immunosuppression Coverage for Kidney Transplant Recipients,” Health Care Financing Review, Vol. 30, 2008, p. 95.
[18]
E. Erek, M. S. Sever, E. Akoglu, et al., “Cost of Renal Replacement Therapy in Turkey,” Nephrology, Vol. 9, No. 1, 2004, pp. 33-38. http://dx.doi.org/10.1111/j.1440-1797.2003.00218.x
